| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA665988 | B | In silico binding affinity to human corticosteriod binding globulin | 31 | ALA1130169 | single protein format | Scientific Literature | ||
| 2. | ALA665992 | B | In silico binding affinity to corticosteroid binding globulin (CBG) | 31 | ALA1130276 | single protein format | Scientific Literature | ||
| 3. | ALA665993 | B | Compound was evaluated for its binding affinity towards the human corticosteroid binding globulin | 10 | ALA1132579 | single protein format | Scientific Literature | ||
| 4. | ALA663464 | B | In silico steroid binding affinity to transport protein corticosteroid binding globulin | 31 | ALA1127742 | single protein format | Scientific Literature | ||
| 5. | ALA681326 | B | Inhibition of human Farnesyltransferase at 100 uM | Homo sapiens | 3 | ALA1131170 | protein complex format | Scientific Literature | |
| 6. | ALA1040691 | F | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | ALA1156829 | organism-based format | Novartis Malaria Screening | |
| 7. | ALA1040692 | F | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | ALA1156829 | organism-based format | Novartis Malaria Screening | |
| 8. | ALA1040693 | T | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | Homo sapiens | 5,614 | ALA1156829 | cell-based format | Novartis Malaria Screening | |
| 9. | ALA1040694 | F | NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. | 5,614 | ALA1156829 | assay format | Novartis Malaria Screening | ||
| 10. | ALA2354254 | F | PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) | 153,867 | ALA1201862 | assay format | PubChem BioAssays | ||
| 11. | ALA3561990 | F | PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel. (Class of assay: confirmatory) | 2,189 | ALA1201862 | assay format | PubChem BioAssays | ||
| 12. | ALA3562064 | F | PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel. (Class of assay: confirmatory) | 1,996 | ALA1201862 | assay format | PubChem BioAssays | ||
| 13. | ALA3562110 | F | PubChem BioAssay. A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase. (Class of assay: confirmatory) | 1,981 | ALA1201862 | cell-based format | PubChem BioAssays | ||
| 14. | ALA3562119 | F | PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel. (Class of assay: confirmatory) | 2,170 | ALA1201862 | assay format | PubChem BioAssays | ||
| 15. | ALA3562136 | F | PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel. (Class of assay: confirmatory) | 1,968 | ALA1201862 | assay format | PubChem BioAssays | ||
| 16. | ALA3562146 | F | PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel. (Class of assay: confirmatory) | 1,812 | ALA1201862 | assay format | PubChem BioAssays | ||
| 17. | ALA3562152 | F | PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel. (Class of assay: confirmatory) | 1,822 | ALA1201862 | assay format | PubChem BioAssays | ||
| 18. | ALA4303805 | F | Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging | Homo sapiens | 5,612 | ALA4303101 | organism-based format | SARS-CoV-2 Screening Data 2020-21 | |
| 19. | ALA4495582 | F | SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate | Severe acute respiratory syndrome coronavirus 2 | 7,212 | ALA4495564 | assay format | SARS-CoV-2 Screening Data 2020-21 | |
| 20. | ALA4513082 | F | Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging | Chlorocebus sabaeus | 7,212 | ALA4495565 | organism-based format | SARS-CoV-2 Screening Data 2020-21 |
The page will load shortly, Thanks for your patience!